Voxelotor (Oxbryta)

Small molecule

Also known as GBT440

DiscontinuedHemoglobin S (HbS)
WithdrawnUS approval

Evidence outlook · regulatory status

US approval withdrawn: Sickle Cell Disease (FDA, approved 2019-11-25)

The FDA approved this product and later withdrew the approval, so it has no current US approval. The withdrawal took effect on 2026-07-31. Development was discontinued on 2024-09-25, on a safety finding. The trials below are the product's evidence history.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (6)
Other / comorbidity
NCT03573882 · Pfizer
2018-06-06 – 2024-11-12 · Sickle Cell Disease
What this study did
NCT04188509 · Pfizer
2019-11-18 – 2024-11-01 · Sickle Cell Disease
What this study did
NCT05561140 · Pfizer
2022-05-30 – 2024-10-22 · Sickle Cell Disease, Leg Ulcers
What this study did
NCT05228834 · Pfizer
2022-06-24 – 2022-09-30 · Sickle Cell Disease
What this study did
Phase 2 (9)
Other / comorbidity
NCT06023199 · Inova Health Care Services
2023-10-23 – 2026-03-05 · Sickle Cell Disease
What this study did
NCT05199766 · Assistance Publique - Hôpitaux de Paris
2023-03-22 – 2025-03-22 · Sickle Cell Disease
What this study did
NCT05018728 · Emory University
2022-03-28 – 2024-10-22 · Sickle Cell Anemia in Children
What this study did
NCT02850406 · Pfizer
2016-07-05 – 2023-10-02 · Sickle Cell Disease
What this study did
NCT05289570 · Duke University
2022-05-03 – 2023-07-04 · Acute Lung Injury, End Stage Lung Disease
What this study did
NCT04247594 · Pfizer
2020-01-09 – 2021-06-08 · Sickle Cell Disease
What this study did
NCT02846324 · Global Blood Therapeutics
2016-06 – 2017-11 · Idiopathic Pulmonary Fibrosis, Hypoxemia
What this study did
NCT02989168 · Global Blood Therapeutics
2016-11 – 2017-10-23 · Idiopathic Pulmonary Fibrosis, Hypoxemia
What this study did
NCT03041909 · Global Blood Therapeutics
2016-08 – 2017-08 · Sickle Cell Disease
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT04335721 · University of Illinois at Chicago
2021-03-16 – 2024-10-07 · Sickle Cell Disease, Sickle Cell Nephropathy
What this study did
Phase 1 (8)
Other / comorbidity
NCT05981365 · Pfizer
2023-04-17 – 2023-10-04 · Sickle Cell Disease
What this study did
NCT03114540 · Pfizer
2017-03-17 – 2018-03-22 · Hepatic Impairment
What this study did
NCT03051711 · Global Blood Therapeutics
2016-12 – 2018-02-21 · Cardio-pulmonary Function
What this study did
NCT03161015 · Global Blood Therapeutics
2016-11 – 2017-07-06 · Renal Impairment
What this study did
NCT02285088 · Global Blood Therapeutics
2014-12 – 2017-05 · Healthy Subjects, Sickle Cell Disease
What this study did
NCT02497924 · Global Blood Therapeutics
2015-06 – 2016-07 · Anemia, Sickle Cell
What this study did
NCT02567695 · Global Blood Therapeutics
2015-09 – 2016-06 · Sickle Cell Disease
What this study did
NCT02567682 · Global Blood Therapeutics
2015-09 – 2016-05 · Sickle Cell Disease
What this study did
Phase 4 (3)
Other / comorbidity
NCT05228821 · Pfizer
2023-08-09 – 2023-08-23 · Sickle Cell Disease
What this study did
NCT04400487 · Pfizer
2020-12-21 – 2022-09-13 · Sickle Cell Disease, Sickle Cell Anemia
What this study did
NCT04581356 · Elizabeth Yang, MD, PhD
2020-09-21 – 2021-12-29 · Sickle Cell Anemia
What this study did

Competitive landscape

This drug's own stage for Idiopathic Pulmonary Fibrosis: Discontinued. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Voxelotor (Oxbryta): this drugDiscontinuedSmall moleculeHemoglobin S (HbS)not yet gradedNo reviewed efficacy summary in this indication
Nerandomilast (Jascayd)ApprovedSmall moleculePDE4BReliable signal
NCT05321069: Absolute Change From Baseline in Forced Vital Capacity (FVC) [mL] at Week 52 (The MMRM model is a longitudinal analysis, and it incorporated FVC measurements from baseline (Week -8 to Week -1) and Week 2, Week 6, Week 12, Week 18, Week 26, Week 36, Week 44 and Week 52. The data represent the Least Squares Mean at Week 52): Placebo -183.48 Milliliters (mL) (95% CI -210.86 to -156.1) | Nerandomilast 9 mg BID -138.6 Milliliters (mL) (95% CI -165.59 to -111.61) | Nerandomilast 18 mg BID -114.65 Milliliters (mL) (95% CI -141.81 to -87.5)
NCT04419506: The Change From Baseline in Forced Vital Capacity (FVC) at 12 Weeks (Baseline (day 1) and week 12.): Placebo - Antifibrotics at Baseline -77.7 Milliliter (95% CI -124.87 to -30.53) | BI 1015550 - Antifibrotics at Baseline 2.72 Milliliter (95% CI -33.46 to 38.89) | Placebo - Non-antifibrotics at Baseline -95.62 Milliliter (95% CI -157.13 to -34.1) | BI 1015550 - Non-antifibrotics at Baseline 6.1 Milliliter (95% CI -39.67 to 51.88)
Nintedanib (Ofev)ApprovedSmall moleculeTriple angiokinase inhibitor (VEGFR/FGFR/PDGFR)Partial signal
NCT01335464: INPULSIS-1, annual rate of FVC decline over 52 weeks, nintedanib 150 mg twice daily (n=309) vs placebo (n=204): -114.65 vs -239.91 mL/year; difference 125.26 mL/year (95% CI 77.68 to 172.84), p < 0.0001 (CT.gov posted results).
NCT01335477: INPULSIS-2, annual rate of FVC decline over 52 weeks, nintedanib 150 mg twice daily (n=329) vs placebo (n=219): -113.59 vs -207.32 mL/year; difference 93.73 mL/year (95% CI 44.78 to 142.68), p = 0.0002 (CT.gov posted results).
Pirfenidone (Esbriet)ApprovedSmall moleculePyridoneReliable signal
NCT01366209: At week 52, decline in percent predicted FVC of 10 points or more, or death: pirfenidone 16.5% vs placebo 31.8% (relative reduction 47.9%); no FVC decline 22.7% vs 9.7%; P<0.001 (ASCEND, NEJM 2014; CT.gov posted results).
Treprostinil (Tyvaso DPI)
Approved(overall)
Small moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
HSK44459Phase 3Small moleculePDE4Bnot yet gradedNo reviewed efficacy summary in this indication
Treprostinil (Tyvaso)Phase 3Small moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
ABBV-722
Phase 1(overall)
Small moleculeLPAR1not yet gradedNo reviewed efficacy summary in this indication
Iloprost (Ventavis)DiscontinuedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
PamrevlumabDiscontinuedMonoclonal antibodyCTGFnot yet gradedNo reviewed efficacy summary in this indication
ZiritaxestatDiscontinuedSmall moleculeautotaxin (ENPP2)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

31 July 2026WithdrawalPfizer withdraws the Oxbryta NDAs
US, FDA · Source ↗
September 2024WithdrawalPfizer withdraws all lots of Oxbryta in every market where it was approved
Global · Source ↗